Pelacarsen Fails to Reduce Major Cardiovascular Events Despite Lowering Lipoprotein(a) in Landmark Trial

A Phase 3 clinical trial led by Cleveland Clinic, known as Lp(a)HORIZON, found that while the drug pelacarsen significantly reduced lipoprotein(a) (Lp(a)) levels, it did not decrease the risk of major adverse cardiovascular events after nearly five years of follow-up. The results were presented at the American Heart Association's Scientific Sessions 2026 and simultaneously published in the New England Journal of Medicine.

Context

Lipoprotein(a) is a type of cholesterol linked to an increased risk of cardiovascular disease. Pelacarsen was developed to target and lower Lp(a) levels, with hopes that this would lead to fewer heart attacks and strokes. The trial involved nearly five years of follow-up to assess the drug's effectiveness in reducing major cardiovascular events compared to placebo.

Why it matters

The findings from the Lp(a)HORIZON trial challenge the assumption that lowering lipoprotein(a) levels directly correlates with reduced cardiovascular risk. This could impact treatment strategies for patients at risk of heart disease, as pelacarsen was seen as a promising option. Understanding the relationship between Lp(a) and cardiovascular events remains crucial for future research and drug development.

Implications

Patients with high Lp(a) levels may need to reconsider their treatment options, as pelacarsen may not be a viable solution for reducing cardiovascular risk. Healthcare providers may need to focus on other risk factors and treatments for heart disease. The trial results could influence pharmaceutical companies to shift their research efforts towards different therapeutic targets.

What to watch

Researchers will likely analyze the trial data further to understand why pelacarsen did not lead to a reduction in cardiovascular events despite lowering Lp(a). Future studies may explore alternative mechanisms or therapies that could effectively address cardiovascular risk. The medical community will be attentive to any new guidelines or recommendations regarding Lp(a) management.